Treatment of Inhalation Anthrax
Inhalation anthrax represents a systemic anthrax presentation that requires prompt, structured antibiotic management based on established clinical evidence.
Clinical Scenario
This protocol applies to patients presenting with inhalation anthrax, classified as a systemic anthrax presentation given its invasive, disseminated nature.
Treatment Approach
Management involves empiric combination antibiotic therapy, with agent selection guided by local penicillin susceptibility patterns.
References
Systemic anthrax is defined as any of the following: 3) Inhalation anthrax.
In the presence of any of these scenarios, empiric combination therapy with two antibiotics is recommended. The first agent should be selected from ciprofloxacin, ampicillin, or penicillin G, based on local penicillin susceptibility patterns (Table 4). The second agent should be chosen according to the clinical presentation: intravenous clindamycin for inhalation or injection-related anthrax, oral clindamycin for severe cutaneous anthrax, or intravenous gentamicin for gastrointestinal anthrax. Overall, treatment duration should be extended for at least 14 days or until the patient is clinically stable, whichever is longer.
View source ↗